Table 4.

Association of genetic variants with adult onset disease in the UK biobank.

Variant	EA	Type 2 diabetes (n = 19.630)	P value	Hypertension (n = 77,533)	P value	BMI (n = 490,000)	P value
		β ± SE		β ± SE		β ± SE
rs7964361	C	−0.000 ± 0.001	0.935	0.001 ± 0.001	0.554	0.030 ± 0.017	0.067
rs61154119	T	−0.001 ± 0.001	0.129	−0.000 ± 0.001	0.827	0.009 ± 0.013	0.473
rs1374204	T	0.000 ± 0.001	0.412	−0.001 ± 0.001	0.198	0.020 ± 0.01	0.060
rs72851023	T	−0.001 ± 0.001	0.060	−0.003 ± 0.002	0.091	0.051 ± 0.018	0.004
rs700059	G	−0.002 ± 0.001	0.0007	−0.002 ± 0.001	0.034	−0.030 ± 0.014	0.026
rs10830963	G	0.003 ± 0.001	6.37E-11	−0.000 ± 0.001	0.643	0.028 ± 0.010	0.008
rs138715366	C	0.002 ± 0.002	0.490	−0-004 ± 0.004	0.366	0.025 ± 0.050	0.613
rs2150052	T	−0.001 ± 0.000	0.206	−0.002 ± 0.001	0.039	−0.005 ± 0.009	0.600

Analyses assessing the effect of genetic variants associated with intrauterine growth in this study and their impact on adult onset type 2 diabetes, hypertension and BMI in the UK biobank of 19,630–490,000 individuals. Occurrence of Type 2 diabetes and hypertension are based on ICD-10 codes. BMI is measured at inclusion in the UK biobank. EA: Effect allele. P values are calculated by linear regression or logistic regression models.